PAREXEL Introduces its Connected Journey
BOSTON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation, a global biopharmaceutical services provider, announced the launch of its Connected Journey™ of data-driven services. This new network, powered by PAREXEL® Analytics capabilities, combines PAREXEL’s technology and processes, to deliver critical intelligence supporting clinical development and commercialization.
PAREXEL’s Connected Journey consists of over 40 data-driven services. Its most recent, the ForeSite™ clinical trial methodology, integrates therapeutic area expertise, real-time analytics technology, and centralized oversight to predict site productivity. The solution enables sponsors to improve feasibility and site and country selection, as well as to more effectively engage and retain sites and patients.
“While drug companies have access to more data sources than ever before, they face challenges in generating and integrating meaningful insights that drive timely and actionable decisions,” said Mark A. Goldberg, MD, president and COO, PAREXEL. “Aggregating and leveraging the right data to drive value requires a broad range of services working together to generate insights across the entire drug development and commercialization spectrum. We believe PAREXEL’s global scale and broad technical expertise offer clients a uniquely integrated and comprehensive portfolio-delivered by a single provider.”
“The data resources to inform decision making are available, but to yield true value they must all be brought together,” said Xavier Flinois, president, PAREXEL Informatics. “PAREXEL’s Connected Journey moves from single solutions to the industry’s largest system of interrelated data-driven innovations. This model seamlessly connects data, technology, processes and multi-functional expertise, and is designed to foster close collaboration with all constituents.”
Contacts:
Media:
Dana Robie
Tel.: +1 781-434-4772
Email: Dana.Robie@PAREXEL.com
Kathryn McMahon, PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
Investors:
Ronald Aldridge
Tel.: +1-781-434-4753
Email: ron.aldridge@PAREXEL.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
